PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03262415|
Recruitment Status : Recruiting
First Posted : August 25, 2017
Last Update Posted : September 18, 2018
The purpose of this study is to evaluate the accuracy and efficacy of the Cambridge Medical Technologies, LLC LabPatch Continuous Glucose Monitoring (CGM) System compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite.
The LabPatch system includes:
- The LabPatch circuit chip which lies in the center of a circular push-button. The circuit is in the form of a small chip (approximately 15.7 mm [0.618"] x 15.7 mm [0.618"]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.
- A Lab Patch holding device (blue box).
- A wire that connects the chip to a laptop that continuously captures glucose data.
|Condition or disease||Intervention/treatment|
|Type1 Diabetes Mellitus Type 2 Diabetes Mellitus||Device: LabPatch Continuous Glucose Monitoring (CGM)|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor|
|Actual Study Start Date :||February 17, 2017|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||September 2019|
30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
Device: LabPatch Continuous Glucose Monitoring (CGM)
- Mean absolute relative difference (MARD) [ Time Frame: Baseline, every 15 minutes after breakfast for 2 hours, every 30 minutes until lunch time, and every 30 minutes after lunch for 2 hours ]Blood glucose values (mg/dL) from the LabPatch system and reference YSI, One Touch Verio, and FreeStyle Lite will be used to report the mean absolute relative difference (MARD) in Percentage (%).
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03262415
|Contact: Sahar Ashrafzadeh, ABemail@example.com|
|Contact: Shaheen Tomah, MDfirstname.lastname@example.org|
|United States, Massachusetts|
|Joslin Diabetes Center||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Sahar Ashrafzadeh, AB 617-309-4131 email@example.com|
|Contact: Shaheen Tomah, M.D. 617-309-4144 firstname.lastname@example.org|
|Principal Investigator: Osama Hamdy, M.D.|
|Sub-Investigator: Adham Mottalib, M.D.|
|Sub-Investigator: Shaheen Tomah, M.D.|
|Sub-Investigator: Khaled Alsibai, M.D.|
|Principal Investigator:||Osama Hamdy, M.D.,Ph.D||Joslin Diabetes Center|